Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
PDF) Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
63rd Annual Scientific Meeting American Headache Society® - 2021 - Headache: The Journal of Head and Face Pain - Wiley Online Library
Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment - The Lancet Neurology
IHC 2019 Late Breaking Abstracts, 2019
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
Daniele MARTINELLI | PhD Student | Doctor of Medicine | University of Pavia, Pavia | UNIPV | Department of Brain and Behavioral Sciences | Research profile
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
The International Headache Congress – IHS and EHF joint congress 2021: late breaking abstracts | The Journal of Headache and Pain | Full Text
Does erenumab suspension affect chronic migraine course? A real life experience
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
CONCLUSIONS BACKGROUND OBJECTIVE METHODS RESULTS REFERENCES ACKNOWLEDGEMENTS RESULTS (CONTINUED)
PDF) Psychological Predictors of Negative Treatment Outcome with Erenumab in Chronic Migraine: Data From an Open Label Long-Term Prospective Study
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
PDF) Migraine and COVID-19 lockdown
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study | The Journal of Headache and Pain | Full Text
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE
MONOCLONAL ANTIBODIES TARGETING CGRP: FOR WHOM AND FOR HOW LONG'
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial | The Journal of Headache and Pain | Full Text
PDF) Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study - Roberto De Icco, Giuseppe Fiamingo, Rosaria Greco, Sara Bottiroli, Chiara Demartini, Anna Maria Zanaboni, Marta Allena, Elena Guaschino,
